List of Pliaglis drug patents

Pliaglis is owned by Taro Pharms.

Pliaglis contains Lidocaine; Tetracaine.

Pliaglis has a total of 3 drug patents out of which 0 drug patents have expired.

Pliaglis was authorised for market use on 29 June, 2006.

Pliaglis is available in cream;topical dosage forms.

The generics of Pliaglis are possible to be released after 14 January, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603293 TARO PHARMS Solid-forming local anesthetic formulations for pain control
Jan, 2031

(7 years from now)

US10350180 TARO PHARMS Solid-forming local anesthetic formulations for pain control
Jan, 2031

(7 years from now)

US10751305 TARO PHARMS Solid-forming topical formulations for pain control
Jan, 2031

(7 years from now)

Drugs and Companies using LIDOCAINE; TETRACAINE ingredient

Market Authorisation Date: 29 June, 2006

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in